GlassScriptPhysician profile
Jennifer E Lyerly
NPI 1831470350
$163,591.39
in general payments reported to CMS, 2019-2025
17 companies · $4,319 in 2025
The $4,319 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,629 · 2020: $1,140 · 2021: $45K · 2022: $17K · 2023: $6,272 · 2024: $87K · 2025: $4,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Consulting Fee: $5,990 · Food and Beverage: $2,563 · Travel and Lodging: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,000.00 |
| Consulting Fee | $5,990.00 |
| Food and Beverage | $2,563.22 |
| Travel and Lodging | $1,372.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $138,307.29 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $14,837.15 | 2019-2025 | Total30, Precision 7, Precision 1 |
| Coopervision INC. | $7,124.53 | 2019-2025 | Misight Contact Lens, Cvi Contact Lens, Synergeyes Contact Lens |
| Alcon Research LLC | $760.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $543.55 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $541.66 | 2022-2025 | Xiidra, Miebo, Infuse |
| Dompe US, INC. | $254.02 | 2020-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $224.66 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $192.03 | 2025 | Vevye |
| Allergan, INC. | $161.67 | 2019-2022 | |
| Horizon Therapeutics Plc | $138.44 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $126.20 | 2022 | |
| Astellas Pharma US INC | $125.00 | 2024 | Izervay |
| Shire North American Group INC | $115.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $99.39 | 2021-2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $28.41 | 2021-2022 | |
| Biotissue Holdings INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lyerly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.